{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for alpha root_references_citation in Reference Text / Citation (approximate match)
Status:
First approved in 1961
Class:
PROTEIN
Status:
First approved in 1955
Class:
PROTEIN
Status:
Possibly Marketed Outside US
First approved in 1987
Source:
BLA103174
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02497118: Phase 4 Interventional Completed Non Small Cell Lung Cancer
(2010)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT04244383: Phase 4 Interventional Unknown status Hepatitis C
(2020)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2010)
Source URL:
First approved in 2010
Source:
21 CFR 352
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
USAN:COBNABEXAGENE ANVUPARVOVEC HEXB [USAN]
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03074734: Not Applicable Interventional Completed COPD
(2016)
Source URL:
Class:
STRUCTURALLY DIVERSE
